The second article in this series, Standards for Clinical Trials in Male and Female Sexual Dysfunction, focuses on measurement of patient-reported outcomes (PROs). Together with the design of appropriate phase I to phase IV clinical trials, the development, validation, choice, and implementation of valid PRO measurements-the focus of the present article-form the foundation of research on treatments for male and female sexual dysfunctions. PRO measurements are assessments of any aspect of a patient's health status that come directly from the patient (ie, without the interpretation of the patient's responses by a physician or anyone else). PROs are essential for assessing male and female sexual dysfunction and treatment response, including symptom frequency and severity, personal distress, satisfaction, and other measurements of sexual and general health-related quality of life. Although there are some relatively objective measurements of sexual dysfunction (ie, intravaginal ejaculatory latency time, frequency of sexual activity, etc), these measurements do not comprehensively assess the occurrence and extent of sexual dysfunction or treatment on the patient's symptoms, functioning, and well-being. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient's perspective.

Fisher, W., Gruenwald, I., Jannini, E., Lev Sagie, A., Lowenstein, L., Pyke, R., et al. (2016). Standards for Clinical Trials in Male and Female Sexual Dysfunction: II. Patient-Reported Outcome Measures. JOURNAL OF SEXUAL MEDICINE, 13(12), 1818-1827 [10.1016/j.jsxm.2016.08.015].

Standards for Clinical Trials in Male and Female Sexual Dysfunction: II. Patient-Reported Outcome Measures

JANNINI, EMMANUELE ANGELO FRANCESCO;
2016-01-01

Abstract

The second article in this series, Standards for Clinical Trials in Male and Female Sexual Dysfunction, focuses on measurement of patient-reported outcomes (PROs). Together with the design of appropriate phase I to phase IV clinical trials, the development, validation, choice, and implementation of valid PRO measurements-the focus of the present article-form the foundation of research on treatments for male and female sexual dysfunctions. PRO measurements are assessments of any aspect of a patient's health status that come directly from the patient (ie, without the interpretation of the patient's responses by a physician or anyone else). PROs are essential for assessing male and female sexual dysfunction and treatment response, including symptom frequency and severity, personal distress, satisfaction, and other measurements of sexual and general health-related quality of life. Although there are some relatively objective measurements of sexual dysfunction (ie, intravaginal ejaculatory latency time, frequency of sexual activity, etc), these measurements do not comprehensively assess the occurrence and extent of sexual dysfunction or treatment on the patient's symptoms, functioning, and well-being. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient's perspective.
2016
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/13 - ENDOCRINOLOGIA
English
Clinical Trials; Patient-Reported Outcomes; Sexual Dysfunction
Fisher, W., Gruenwald, I., Jannini, E., Lev Sagie, A., Lowenstein, L., Pyke, R., et al. (2016). Standards for Clinical Trials in Male and Female Sexual Dysfunction: II. Patient-Reported Outcome Measures. JOURNAL OF SEXUAL MEDICINE, 13(12), 1818-1827 [10.1016/j.jsxm.2016.08.015].
Fisher, W; Gruenwald, I; Jannini, Eaf; Lev Sagie, A; Lowenstein, L; Pyke, R; Reisman, Y; Revicki, D; Rubio Aurioles, E
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
JSM Standards for Clinical Trials II.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 1.05 MB
Formato Adobe PDF
1.05 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/171241
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact